

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter and Nine Months Ended 31st December, 2018

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Revenue from operations	48.71	29.15	64.69	108.05	157.02	176.24
2	Other income	9.05	7.26	12.64	17.99	19.06	32.86
3	Total Income (1+2)	57.76	36.41	77.33	126.04	176.08	209.10
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-	-
	d) Employee benefits expense	6.05	6.42	7.40	18.03	20.72	28.29
	e) Finance costs	-	-	-	-	-	-
	f) Depreciation and amortization expense	3.60	3.60	3.35	11.22	9.02	12.59
	g) Other expenses	2.38	3.95	15.10	9.71	26.85	34.32
	Total Expenses	12.03	13.97	25.85	38.96	56.59	75.20
5	Profit/(loss) before exceptional and extraordinary items and tax (3-4)	45.73	22.44	51.48	87.08	119.49	133.90
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before extraordinary items and tax (5-6)	45.73	22.44	51.48	87.08	119.49	133.90
8	Extraordinary items	-	-	-	-	-	-
9	Profit/(Loss) before tax (7-8)	45.73	22.44	51.48	87.08	119.49	133.90
10	Tax expense						
	(a) Current tax	5.50	6.00	8.31	15.75	17.81	23.00
	(b) Deferred tax	0.32	0.14	(5.22)	1.01	0.28	(0.20)
	Total Tax Expense	5.82	6.14	3.09	16.76	18.09	22.80
11	Profit/(Loss) for the Period (9-10)	39.91	16.30	48.39	70.32	101.40	111.10
12	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or loss	15.94	(1.95)	83.25	(2.13)	144.65	75.00
	(b) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	15.94	(1.95)	83.25	(2.13)	144.65	75.00
	Total Comprehensive income (11+12)	55.85	14.35	131.64	68.19	246.05	186.10
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	-	-	1,249.73
15	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	0.59	0.24	0.72	1.04	1.50	1.65
	(2) Diluted	0.59	0.24	0.72	1.04	1.50	1.65

Segment wise Revenue, Results and Capital Employed for the Quarter & Nine Months ended 31st December, 2018

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates	26.00	25.50	32.19	68.50	78.10	112.10
	b) Investments	31.76	10.91	45.14	57.54	97.98	97.00
	Total	57.76	36.41	77.33	126.04	176.08	209.10
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	57.76	36.41	77.33	126.04	176.08	209.10
2	Segment Results Profit/ (Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates	22.13	21.82	23.90	56.12	63.19	93.14
	b) Investments	31.76	10.91	45.14	57.54	97.98	97.00
	Total	53.89	32.73	69.04	113.66	161.17	190.14
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	8.16	10.29	17.56	26.58	41.68	56.24
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	45.73	22.44	51.48	87.08	119.49	133.90
3	Capital Employed						
	(Segment assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	337.71	322.04	414.66	337.71	414.66	409.75
	b) Investments	1,711.27	1,671.09	1,625.09	1,711.27	1,625.09	1,571.04
	Total	2,048.98	1,993.13	2,039.75	2,048.98	2,039.75	1,980.79

Notes :

- 1 The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 13th February, 2019.
- 2 The Statutory Auditors have Carried out the Limited Review of the Results for the quarter and nine months ended 31st December, 2018.
- 3 Previous year / period figures have been recasted / regrouped / reclassified wherever necessary to make them comparable with current year / period figures.

By Order of the Board
for Sigachi Laboratories Limited

(T.R.Sekhar)
Executive Director
DIN:02943146

Place : Hyderabad
Date : 13.02.2019

niranjan & narayan

Chartered Accountants

first floor, h.no: 7-1-28/1/A/21
shyamkaran road, ameerpeta
hyderabad - 500 016
tel : 29806074, cell : 9490189487
email : caniranjan@yahoo.com
www.nncas.com

INDEPENDENT AUDITOR'S REVIEW REPORT

To

The Board of Directors
Sigachi Laboratories Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited ("the company") for the quarter and Nine months ended 31st December, 2018 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the applicable Indian Accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 13.02.2019
Place: Hyderabad

For Niranjan & Narayan
Chartered Accountants
ERN: 005899S



M.Niranjan
Partner - Memb No.029552

